APA (7th ed.) Citation

O, H., E, H., J, W., A, B., S, S., C, T., . . . M, D. (2016). Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): A randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet (London, England), 388(10044), 565. https://doi.org/10.1016/S0140-6736(16)00739-X

Chicago Style (17th ed.) Citation

O, Hermine, et al. "Addition of High-dose Cytarabine to Immunochemotherapy Before Autologous Stem-cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Randomised, Open-label, Phase 3 Trial of the European Mantle Cell Lymphoma Network." Lancet (London, England) 388, no. 10044 (2016): 565. https://doi.org/10.1016/S0140-6736(16)00739-X.

MLA (9th ed.) Citation

O, Hermine, et al. "Addition of High-dose Cytarabine to Immunochemotherapy Before Autologous Stem-cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Randomised, Open-label, Phase 3 Trial of the European Mantle Cell Lymphoma Network." Lancet (London, England), vol. 388, no. 10044, 2016, p. 565, https://doi.org/10.1016/S0140-6736(16)00739-X.